These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17967816)

  • 1. Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS).
    Drewe E; Powell RJ; McDermott EM
    Rheumatology (Oxford); 2007 Dec; 46(12):1865-6. PubMed ID: 17967816
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review.
    Gilbert KE; Manalo IF; Wu JJ
    J Am Acad Dermatol; 2015 Aug; 73(2):329-31. PubMed ID: 26183982
    [No Abstract]   [Full Text] [Related]  

  • 3. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
    Chastek B; Fox KM; Watson C; Gandra SR
    Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS).
    Jacobelli S; André M; Alexandra JF; Dodé C; Papo T
    Rheumatology (Oxford); 2007 Jul; 46(7):1211-2. PubMed ID: 16935919
    [No Abstract]   [Full Text] [Related]  

  • 5. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.
    Moots RJ; Haraoui B; Matucci-Cerinic M; van Riel PL; Kekow J; Schaeverbeke T; Davis A; Tedeschi MA; Freundlich B; Chang DJ; Singh A
    Clin Exp Rheumatol; 2011; 29(1):26-34. PubMed ID: 21345289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of biologic agents in early rheumatoid arthritis.
    Kavanaugh A; Keystone EC
    Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S203-8. PubMed ID: 14969079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients.
    Drewe E; McDermott EM; Powell PT; Isaacs JD; Powell RJ
    Rheumatology (Oxford); 2003 Feb; 42(2):235-9. PubMed ID: 12595616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry.
    Serac G; Tubach F; Mariette X; Salmon-Céron D; Ravaud P; Lioté F; Laharie D; Ziza JM; Marguerie L; Bonnet C; Falgarone G; Nicolas N; Lortholary O; Chosidow O
    J Invest Dermatol; 2012 Mar; 132(3 Pt 1):726-9. PubMed ID: 22113472
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment with infliximab of a patient with tumor necrosis factor-associated periodic syndrome (TRAPS) who failed to respond to etanercept.
    Krelenbaum M; Chaiton A
    J Rheumatol; 2010 Aug; 37(8):1780-2. PubMed ID: 20675856
    [No Abstract]   [Full Text] [Related]  

  • 10. Modified regimen of etanercept for tumor necrosis factor receptor associated periodic syndrome (TRAPS) like illness.
    Dhanrajani A; Khubchandani RP
    Indian Pediatr; 2014 Jan; 51(1):55-7. PubMed ID: 24561467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome.
    Takada K; Aksentijevich I; Mahadevan V; Dean JA; Kelley RI; Kastner DL
    Arthritis Rheum; 2003 Sep; 48(9):2645-51. PubMed ID: 13130485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS).
    Siebert S; Amos N; Lawson TM
    Rheumatology (Oxford); 2008 Feb; 47(2):228-9. PubMed ID: 18056150
    [No Abstract]   [Full Text] [Related]  

  • 13. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever.
    Marchetti F; Barbi E; Tommasini A; Oretti C; Ventura A
    Clin Exp Rheumatol; 2004; 22(6):791-2. PubMed ID: 15638064
    [No Abstract]   [Full Text] [Related]  

  • 15. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
    Schabert VF; Bruce B; Ferrufino CF; Globe DR; Harrison DJ; Lingala B; Fries JF
    Curr Med Res Opin; 2012 Apr; 28(4):569-80. PubMed ID: 22236091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
    Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
    J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.
    Ramírez-Herráiz E; Escudero-Vilaplana V; Alañón-Plaza E; Trovato-López N; Herranz-Alonso A; Morell-Baladrón A; Sanjurjo-Sáez M
    Clin Exp Rheumatol; 2013; 31(4):559-65. PubMed ID: 23710583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis.
    Kallinich T; Briese S; Roesler J; Rudolph B; Sarioglu N; Blankenstein O; Keitzer R; Querfeld U; Haffner D
    J Rheumatol; 2004 Dec; 31(12):2519-22. PubMed ID: 15570662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM; Gandra SR; Fox KM; Wilson KL
    J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.